* Regeneron Pharmaceuticals Inc., Tarrytown, N.Y., was issuedU.S. patent No. 5,349,056 covering second-generation ciliaryneurotrophic factor, and No. 5,349,055 covering second-generationnerve growth factor.* Xoma Corp., Berkeley, Calif., was issued U.S. patent No.5,348,942 covering a method for neutralizing the anti-coagulanteffect of heparin by administration of bactericidal/permeability-increasing protein products.* Avid Therapeutics Inc., Philadelphia, was issued U.S. patent No.5,334,524, which includes covering a composition of mattercomprising a Hepatitis B Polymerase gene product and an RNAtemplate for hepadnavirus minus strand DNA synthesis; and No.5,334,492 covering a herpes gene product.

(c) 1997 American Health Consultants. All rights reserved.